Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR [epithelial growth factor receptor]

Trial Profile

Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR [epithelial growth factor receptor]

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2010

At a glance

  • Drugs Bortezomib (Primary) ; Cetuximab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Apr 2010 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov record.
    • 16 Apr 2010 Actual number of patients (37) added as reported by ClinicalTrials.gov record.
    • 16 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top